Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H. Kaufmann AM, et al. Among authors: rankin em. Clin Cancer Res. 2002 Dec;8(12):3676-85. Clin Cancer Res. 2002. PMID: 12473576
Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group.
Kaye SB, Paul J, Cassidy J, Lewis CR, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Atkinson RJ, Soukop M, Rankin EM, Davis JA, Reed NS, Crawford SM, MacLean A, Parkin D, Sarkar TK, Kennedy J, Symonds RP. Kaye SB, et al. Among authors: rankin em. J Clin Oncol. 1996 Jul;14(7):2113-9. doi: 10.1200/JCO.1996.14.7.2113. J Clin Oncol. 1996. PMID: 8683244 Clinical Trial.
Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC. Luiten RM, et al. Among authors: rankin em. J Clin Oncol. 2005 Dec 10;23(35):8978-91. doi: 10.1200/JCO.2005.01.6816. Epub 2005 Oct 31. J Clin Oncol. 2005. PMID: 16260696 Clinical Trial.
Hypersensitivity reaction to epirubicin.
Cassidy J, Rankin EM. Cassidy J, et al. Among authors: rankin em. Med Oncol Tumor Pharmacother. 1989;6(4):297-8. doi: 10.1007/BF02985165. Med Oncol Tumor Pharmacother. 1989. PMID: 2615533
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
Rudd RM, Gower NH, Spiro SG, Eisen TG, Harper PG, Littler JA, Hatton M, Johnson PW, Martin WM, Rankin EM, James LE, Gregory WM, Qian W, Lee SM. Rudd RM, et al. Among authors: rankin em. J Clin Oncol. 2005 Jan 1;23(1):142-53. doi: 10.1200/JCO.2005.03.037. J Clin Oncol. 2005. PMID: 15625369 Clinical Trial.
79 results